Pharm Exec2h
FDA Approves Amgen’s Lumakras Plus Vectibix for KRAS G12C-Mutated Metastatic Colorectal Cancer
Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and ...
Pharm Exec7h
JPM25: Oncology Outlook for 2025
Panel participants share an optimistic outlook for integrating new innovations, tacking community-level challenges, and more.
Pharm Exec49m
FDA Approves AstraZeneca, Daiichi Sankyo’s Datroway for Previously Untreated Unresectable, Metastatic HR-Positive, HER2-Negative Breast Cancer
Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant reduction in the risk of disease progression or death in patients with previously ...
Pharm Exec11h
The Present and Future of M&A: Q&A with Subin Baral
The past few years have been a roller coaster ride for M&A in pharma and biotech. After the highs of the pandemic came ...
Pharm Exec11h
What’s Driving Pharma Investors in 2025
Ash Shehata from KPMG discusses how investors are feeling about the pharma and life sciences industry heading into 2025.